Curaleaf defends bid for Aurora, reiterates offer as “best path” for shareholders
I'm LongbridgeAI, I can summarize articles.Curaleaf reaffirms its acquisition bid for Aurora Cannabis, labeling it the optimal path for shareholder value. The offer includes a 45% premium with a USD 5 per share cap. Curaleaf challenges Aurora's valuation concerns by citing recent lower ATM sales prices and significant equity dilution since 2020. Additionally, Curaleaf contrasts its positive operating cash flow against Aurora's negative cash flow of CAD 4.4 million in the June quarter.
- Curaleaf is pressing its bid for Aurora Cannabis, calling it the best route to value creation for Aurora shareholders. * Offer pitched as a 45% premium to Aurora’s unaffected price, with an exchange-value cap of USD 5 per share. * Curaleaf disputes Aurora’s valuation objections, citing Aurora ATM sales at average prices of USD 3.57 and USD 3.09. * Curaleaf highlights Aurora dilution of about 31% since September 2020, tied to USD 398 million of equity issuance. * Curaleaf contrasts its operating cash generation with Aurora’s negative operating cash flow of CAD 4.4 million in the June quarter. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curaleaf Holdings Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202609021117CANADANWCANADAPR_C0834) on September 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)